Clinical Trial: SWOG S1602

SWOG S1602

Status: Closed

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer

S1602 is permanently close to accrual, effective December 15, 2020.